OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study)
Dominik Strzelecki, Małgorzata Urban‐Kowalczyk, Adam Wysokiński
Psychiatry Research (2018) Vol. 268, pp. 447-453
Closed Access | Times Cited: 15
Dominik Strzelecki, Małgorzata Urban‐Kowalczyk, Adam Wysokiński
Psychiatry Research (2018) Vol. 268, pp. 447-453
Closed Access | Times Cited: 15
Showing 15 citing articles:
Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies
Jeffrey R. Bishop, Lusi Zhang, Paulo Lizano
Harvard Review of Psychiatry (2022) Vol. 30, Iss. 1, pp. 59-70
Open Access | Times Cited: 68
Jeffrey R. Bishop, Lusi Zhang, Paulo Lizano
Harvard Review of Psychiatry (2022) Vol. 30, Iss. 1, pp. 59-70
Open Access | Times Cited: 68
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson’s disease
Can Cui, Yingying Han, Hongxia Li, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 63
Can Cui, Yingying Han, Hongxia Li, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 63
The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
Bahareh Peyrovian, Joshua D. Rosenblat, Zihang Pan, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 92, pp. 387-404
Closed Access | Times Cited: 63
Bahareh Peyrovian, Joshua D. Rosenblat, Zihang Pan, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 92, pp. 387-404
Closed Access | Times Cited: 63
The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review
Melisa Kose, Carmine M. Pariante, Paola Dazzan, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 40
Melisa Kose, Carmine M. Pariante, Paola Dazzan, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 40
Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials
Kah Kheng Goh, Tzu‐Hua Wu, Chun-Hsin Chen, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 3, pp. 236-252
Closed Access | Times Cited: 39
Kah Kheng Goh, Tzu‐Hua Wu, Chun-Hsin Chen, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 3, pp. 236-252
Closed Access | Times Cited: 39
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
Chun-Hung Chang, Chieh‐Hsin Lin, Chieh‐Yu Liu, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 5, pp. 495-505
Closed Access | Times Cited: 36
Chun-Hung Chang, Chieh‐Hsin Lin, Chieh‐Yu Liu, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 5, pp. 495-505
Closed Access | Times Cited: 36
Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia
Ju-Chun Pei, Da-Zhong Luo, Shiang-Shin Gau, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 30
Ju-Chun Pei, Da-Zhong Luo, Shiang-Shin Gau, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 30
Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Mattia Marchi, G. Galli, Federica Maria Magarini, et al.
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 4, pp. 483-493
Closed Access | Times Cited: 22
Mattia Marchi, G. Galli, Federica Maria Magarini, et al.
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 4, pp. 483-493
Closed Access | Times Cited: 22
Serum Levels of Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in the Subtypes of Clinical High Risk Individuals: A Prospective Cohort Study
JiaYi Ye, YanYan Wei, Jiahui Zeng, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 1711-1723
Open Access | Times Cited: 8
JiaYi Ye, YanYan Wei, Jiahui Zeng, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 1711-1723
Open Access | Times Cited: 8
Ketamine, benzoate, and sarcosine for treating depression
Yu‐Jung Cheng, Chieh‐Hsin Lin, Hsien‐Yuan Lane
Neuropharmacology (2022) Vol. 223, pp. 109351-109351
Closed Access | Times Cited: 11
Yu‐Jung Cheng, Chieh‐Hsin Lin, Hsien‐Yuan Lane
Neuropharmacology (2022) Vol. 223, pp. 109351-109351
Closed Access | Times Cited: 11
Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence
Pál Czobor, Brigitta Kakuszi, István Bitter
Schizophrenia Bulletin (2022) Vol. 48, Iss. 6, pp. 1228-1240
Open Access | Times Cited: 10
Pál Czobor, Brigitta Kakuszi, István Bitter
Schizophrenia Bulletin (2022) Vol. 48, Iss. 6, pp. 1228-1240
Open Access | Times Cited: 10
A possible role for sarcosine in the management of schizophrenia
David Curtis
The British Journal of Psychiatry (2019) Vol. 215, Iss. 6, pp. 697-698
Open Access | Times Cited: 15
David Curtis
The British Journal of Psychiatry (2019) Vol. 215, Iss. 6, pp. 697-698
Open Access | Times Cited: 15
Do damaging variants of SLC6A9, the gene for the glycine transporter 1 (GlyT-1), protect against schizophrenia?
David Curtis
Psychiatric Genetics (2020) Vol. 30, Iss. 5, pp. 150-152
Open Access | Times Cited: 2
David Curtis
Psychiatric Genetics (2020) Vol. 30, Iss. 5, pp. 150-152
Open Access | Times Cited: 2
Do damaging variants of SLC6A9, the gene for the glycine transporter 1 (GlyT-1), protect against schizophrenia?
David Curtis
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access
David Curtis
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access
Glycine transporter inhibitors
Vjekoslav Peitl, Darko Vlahović
Archives of Psychiatry Research (2020) Vol. 56, Iss. 1, pp. 83-86
Open Access
Vjekoslav Peitl, Darko Vlahović
Archives of Psychiatry Research (2020) Vol. 56, Iss. 1, pp. 83-86
Open Access
